Back to Journals » OncoTargets and Therapy » Volume 11
Original Research
Low-dose hypomethylating agent decitabine in combination with aclacinomycin and cytarabine achieves a better outcome than standard FLAG chemotherapy in refractory/relapsed acute myeloid leukemia patients with poor-risk cytogenetics and mutations
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
8,872 | Dovepress* | 8,246+ | 825 | 9,071 | |
PubMed Central* | 626 | 184 | 810 | ||
Totals | 8,872 | 1,009 | 9,881 | ||
*Since 12 October 2018 |
View citations on PubMed Central and Google Scholar